Uploaded March 2019 | Updated September 2026, 2 weeks ago
How a Bispecific Antibody Could Treat NRG1+ Cancers | Merus
NRG1+ cancers are a rare but aggressive type of cancer that are driven by a genetic alteration called NRG1 fusion. This fusion activates a signaling pathway that promotes tumor growth and survival, and makes the cancer resistant to many therapies.
But what if there was a way to block this pathway and stop the cancer in its tracks?
That’s where MCLA-128 comes in. MCLA-128 is a bispecific antibody that targets two proteins on the surface of cancer cells: HER2 and HER3. By binding to both proteins, MCLA-128 prevents the NRG1 fusion from activating the pathway, and mobilizing a patient’s immune response to fight cancer.
MCLA-128 is being developed by Merus, a biotechnology company that uses its proprietary Multiclonics® platform to create innovative bispecific antibodies. Multiclonics® are full-length human antibodies that can bind to two different targets with high specificity and potency.
In this video, we will explain how MCLA-128 works, what are the benefits of bispecific antibodies in patients with NRG1+ cancers.
If you want to learn more about Merus and its pipeline of bispecific antibodies, visit their website here: https://merus.nl/
Don’t forget to like, share, and subscribe for more videos on cutting-edge cancer treatments. Thanks for watching!
CONTENT
00:00 Cancers relies on receptors of the HER family
00:20 HER3 Receptor Activation
00:31 HER2/HER3 Heterodimer
00:45 Cell Proliferation
00:58 MCLA-128
01:27 DOCK & BLOCK™ Mechanism
01:52 Cancer Therapy
SOURCE
https://merus.nl/technology/multiclonics-platform/
#science #scienceanimation #medicalanimation
FOLLOW US
---------------------------------------------------
Twitter: twitter.com/nymus3d
Facebook: facebook.com/Nymus-3D-136350366438784
LinkedIn: linkedin.com/company/demcon-nymus-3d
Xing: xing.com/pages/demconnymus3d
Instagram: instagram.com/demcon_nymus3d
Behance: behance.net/demcon-nymus3d
Artstation: artstation.com/demcon_nymus3d
► More videos from Nymus 3D: nymus3d.com
How a Bispecific Antibody Could Treat NRG1+ Cancers | Merus
NRG1+ cancers are a rare but aggressive type of cancer that are driven by a genetic alteration called NRG1 fusion. This fusion activates a signaling pathway that promotes tumor growth and survival, and makes the cancer resistant to many therapies.
But what if there was a way to block this pathway and stop the cancer in its tracks?
That’s where MCLA-128 comes in. MCLA-128 is a bispecific antibody that targets two proteins on the surface of cancer cells: HER2 and HER3. By binding to both proteins, MCLA-128 prevents the NRG1 fusion from activating the pathway, and mobilizing a patient’s immune response to fight cancer.
MCLA-128 is being developed by Merus, a biotechnology company that uses its proprietary Multiclonics® platform to create innovative bispecific antibodies. Multiclonics® are full-length human antibodies that can bind to two different targets with high specificity and potency.
In this video, we will explain how MCLA-128 works, what are the benefits of bispecific antibodies in patients with NRG1+ cancers.
If you want to learn more about Merus and its pipeline of bispecific antibodies, visit their website here: https://merus.nl/
Don’t forget to like, share, and subscribe for more videos on cutting-edge cancer treatments. Thanks for watching!
CONTENT
00:00 Cancers relies on receptors of the HER family
00:20 HER3 Receptor Activation
00:31 HER2/HER3 Heterodimer
00:45 Cell Proliferation
00:58 MCLA-128
01:27 DOCK & BLOCK™ Mechanism
01:52 Cancer Therapy
SOURCE
https://merus.nl/technology/multiclonics-platform/
#science #scienceanimation #medicalanimation
FOLLOW US
---------------------------------------------------
Twitter: twitter.com/nymus3d
Facebook: facebook.com/Nymus-3D-136350366438784
LinkedIn: linkedin.com/company/demcon-nymus-3d
Xing: xing.com/pages/demconnymus3d
Instagram: instagram.com/demcon_nymus3d
Behance: behance.net/demcon-nymus3d
Artstation: artstation.com/demcon_nymus3d
► More videos from Nymus 3D: nymus3d.com
